Showing 1 posts of 1 posts found.
Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
How will biomarker-led diagnostics reshape respiratory medicine?
Five Facts about COPD
“That gap between innovation and delivery was what stood out to me most”
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study